Indeed, drugs targeting mutant GBA1 could reduce the progression of PD by halting the activity of glucocerebrosidase and increasing activity in cellular and mice models along with a reduction in SNCA accumulation (Fernandes et al., 2016; Parnetti et al., 2017). Here, GBA1 is linked to Parkinson disease.